News Summary: Amgen posts higher 2Q sales, profit

Published



QUITE A QUARTER: Biotech giant Amgen surprised Wall Street with revenue of $4.48 billion, $400 million above expectations, and profit of $1.43 billion or $1.83 per share, 29 cents more than anticipated. Its stock jumped more than 5 percent.

PERFORMANCE KEYS: Most Amgen drugs had higher sales, and the company got a one-time $206 million gain from selling its share of an experimental lung cancer drug.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.